Recordati announced the successful completion of the acquisition from Novartis of worldwide rights to Signifor and Signifor LAR for the...
Novartis announced that the FDA has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the...
Novartis presented results from a pivotal Phase III trial of investigational therapy Signifor LAR (pasireotide LAR; SOM230) in patients with...
Results of the largest Phase III study of Acromegaly patients, PASPORT-ACROMEGALY, show the novel therapy Signifor ( pasireotide) long-acting release...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for...
The FDA has approved Signifor (pasireotide) injection from Novartis, for the treatment of adult patients with Cushing's Disease for whom...
Strongbridge Biopharma announced the top-line findings from the extended evaluation phase of the pivotal Phase III SONICS study of Recorlev...
The FDA Endocrinologic and Metabolic Drugs Advisory Committee has voted unanimously in support of the use of Signifor (pasireotide) from...
Strongbridge Biopharma plc, announced top-line results from the multinational, pivotal Phase III SONICS study evaluating Recorlev (levoketoconazole) for the treatment...
Novartis announced that the European Commission has approved Signifor (pasireotide) for the treatment of adult patients with Cushing's Disease for...